ALN-ANG3

DRUG2 trials

Sponsors

Regeneron Pharmaceuticals

Conditions

Diabetic Kidney Disease (DKD)Healthy Volunteers With Hyperlipidemia

Phase 1

A First In Human (FIH) Study to Learn if Different Doses of ALN-ANG3 Are Safe and Well Tolerated in Healthy Adults

Active, not recruitingNCT06452771

Regeneron PharmaceuticalsHealthy Volunteers With Hyperlipidemia

Start: 2024-06-27End: 2026-12-04Updated: 2026-02-20

Phase 2

Study to Assess the Effects of Angiopoietin-like Protein 3 (ANGPTL3) Inhibition in Adult Participants With Diabetic Kidney Disease

RecruitingNCT07271186

Regeneron PharmaceuticalsDiabetic Kidney Disease (DKD)

Start: 2026-01-09End: 2028-04-07Target: 270Updated: 2026-03-17